Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (1349) Stock Overview
Engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
1349 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.26 |
| 52 Week High | HK$5.29 |
| 52 Week Low | HK$2.13 |
| Beta | -0.060 |
| 1 Month Change | -10.19% |
| 3 Month Change | -21.07% |
| 1 Year Change | 16.85% |
| 3 Year Change | 15.60% |
| 5 Year Change | -17.47% |
| Change since IPO | 307.50% |
Recent News & Updates
Recent updates
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) 33% Price Boost Is Out Of Tune With Revenues
Jul 30
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) 26% Share Price Surge Not Quite Adding Up
Jun 12Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's (HKG:1349) Problems Go Beyond Poor Profit
Nov 04There's Reason For Concern Over Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) Massive 51% Price Jump
Oct 14Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders
May 06What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21Shareholder Returns
| 1349 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -2.1% | 1.0% | -1.0% |
| 1Y | 16.8% | 56.6% | 27.5% |
Return vs Industry: 1349 underperformed the Hong Kong Pharmaceuticals industry which returned 56.6% over the past year.
Return vs Market: 1349 underperformed the Hong Kong Market which returned 27.5% over the past year.
Price Volatility
| 1349 volatility | |
|---|---|
| 1349 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 1349 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1349's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 899 | Da Jun Zhao | www.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and HER2 ADC that is in phase I clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which has completed Phase IV clinical trial; and Aminolevulinic acid–CIN, which has completed Phase II clinical trials for cervical diseases infected by HPV; Aminolevulinic acid–AK, which is in phase II clinical trials for Actinic keratosis; Aminolevulinic acid–acne, which is in phase II clinical trials for Acne; Aminolevulinic acid–gliomas for surgical visualization of gliomas; Aminolevulinic acid–bladder for surgical visualization of bladder cancer; and Aminolevulinic acid–breast for surgical visualization of breast cancer.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary
| 1349 fundamental statistics | |
|---|---|
| Market cap | HK$8.07b |
| Earnings (TTM) | -HK$68.37m |
| Revenue (TTM) | HK$776.34m |
Is 1349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1349 income statement (TTM) | |
|---|---|
| Revenue | CN¥711.63m |
| Cost of Revenue | CN¥73.43m |
| Gross Profit | CN¥638.20m |
| Other Expenses | CN¥700.87m |
| Earnings | -CN¥62.67m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 89.68% |
| Net Profit Margin | -8.81% |
| Debt/Equity Ratio | 0.2% |
How did 1349 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/05 02:01 |
| End of Day Share Price | 2025/11/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Hu | Deutsche Bank |
| Feng Qiang Sun | Guotai Junan International Holdings Limited |
| Xiang Jun | Industrial Securities Co. Ltd. |